Skip to content
The Nexus
DossierENTITY

abatacept

Coverage of abatacept in the Nexus archive.

Earliest in view: Jun 1 · 13:25 UTCMost recent: Jun 1 · 13:25 UTC
Co-mentioned in this coverage
rheumatoid arthritistopic1immune-targeting drugtopic1
Recent coverage
  • HEALTHJun 1 · 13:25 UTCSCIENCE DAILY
    This drug delayed rheumatoid arthritis for years after treatment ended

    A study found that one year of treatment with the immune-targeting drug abatacept delayed rheumatoid arthritis onset by up to four years in high-risk individuals, with benefits persisting after treatment ended. The results suggest rheumatoid arthritis may not be inevitable for those at high risk.